Monographie - Esomeprazole sodium

Viimeisin päivitys :
14/12/2024

Esomeprazole sodium

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adptor	Meksiko
Axagon	Italia
Axiago	Ruotsi
Cativa	Ruotsi
Cronopep	Kolumbia, Marokko
Eliprot	Ecuador
Emune	Ecuador
Epral	Chile
Esio	Ecuador
Esmonat	Intia, Turkki
Esoblok	Turkki
Esofax	Ecuador
Esolium	Marokko
Esomep	Sveitsi
Esomeprazol	Chile, Ecuador, Espanja, Kolumbia, Romania
Esomeprazole	Yhdysvallat
Esopral	Italia, Ruotsi
Esopran	Marokko
Esoton Plus	Marokko
Esoz	Intia, Kolumbia
Ezole	Marokko
Gletop	Venezuela
Inexium	Ranska
Milenium	Ecuador
Nexiam	Belgia, Luxemburg
Nexium	Argentiina, Chile, Ecuador, Egypti, Espanja, Irlanti, Islanti, Iso-Britannia, Italia, Kolumbia, Kreikka, Malesia, Meksiko, Norja, Portugali, Romania, Ruotsi, Saksa, Saudi-Arabia, Sveitsi, Turkki, Venezuela, Yhdistyneet arabiemiirikunnat, Yhdysvallat
Redica	Ruotsi
Refexxin	Ruotsi

Viitteet : Esomeprazole sodium

	tyyppi	julkaisu
1506	Lehti	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Lehti	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2262	Lehti	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Lehti	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270	Lehti	Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J. Physical and chemical stability of esomeprazole sodium solutions. Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284	Laboratorio	Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics Astra Zenaca 2007
2311	Lehti	Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. J Clin Pharm Ther 2009 ; 34: 25-31.
3249	Lehti	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Lehti	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorio	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3372	Lehti	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429	Lehti	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3827	ilmoitus	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	ilmoitus	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	ilmoitus	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Lehti	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Lehti	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
4055	Lehti	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Lehti	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Lehti	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4465	Lehti	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528	Lehti	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4650	Laboratorio	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	Lehti	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales